Testing And Treatment For Prostate Cancer In Australia: Epidemiology And Modelling
Funder
National Health and Medical Research Council
Funding Amount
$267,886.00
Summary
We aim to use observational data and mathematical modelling to investigate testing and treatment for prostate cancer in Australia. We will incorporate changes in prostate-specific antigen (PSA) testing and in clinical practice to investigate: a) over-diagnosis, being cancer cases diagnosed through PSA testing that would not have been otherwise diagnosed; b) the effect of PSA testing on prostate cancer mortality; and c) mortality and health care use under different PSA test scenarios.
Who To Treat, When To Treat And How To Treat Prostate Cancer: Generating Evidence To Guide Prostate Cancer Treatment Decisions
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
There is considerable uncertainty about which treatments lead to better outcomes for men with prostate cancer and whether treatment is always necessary. This project will compare different treatment options for prostate cancer, including active surveillance, to determine which offers the best chance of survival and least harm to men’s physical and mental wellbeing. It will also explore whether some men who do not receive active treatment (healthy older men) would benefit if they did.
Investigating The Utility Of Primary Care Skin Cancer Clinics In Queensland
Funder
National Health and Medical Research Council
Funding Amount
$187,000.00
Summary
Skin cancer is the most common cancer in Australia, with an estimated 375,000 people being treated for some skin cancer in Australia in 2002, and 1462 dying from the disease (mainly from melanoma) in 2001. Australia has the highest rate of skin cancer, both melanoma and non-melanoma is the world. However, if detected early, skin cancer is curable, and the focus of current treatment programs internationally is to detect the disease before it progresses to an advanced stage. A large proportion of ....Skin cancer is the most common cancer in Australia, with an estimated 375,000 people being treated for some skin cancer in Australia in 2002, and 1462 dying from the disease (mainly from melanoma) in 2001. Australia has the highest rate of skin cancer, both melanoma and non-melanoma is the world. However, if detected early, skin cancer is curable, and the focus of current treatment programs internationally is to detect the disease before it progresses to an advanced stage. A large proportion of skin cancers are first detected by the non-medical community. However, due to the two-tiered medical system in Australia, a person first seeks medical opinion from a general practitioner (GP), who acts as a gatekeeper for further treatment from a specialist. Therefore the ability of GPs to be able to discern which lesions require further treatment is crucial, both for the patient, and the financial burden on the health system. A recent development has been the establishment of dedicated primary skin care clinics, which offer open access consultations to the community for the diagnosis and treatment of skin cancers and pigmented lesions. The emergence of these clinics has created much debate in the medical media. Concern has been expressed about the skills of practitioners in these clinics, whilst others argue that sub-specialisation in primary care will lead to improvements in the management of patients. As there is currently no data on the volume, casemix and diagnostic accuracy of these clinics it is difficult to assess the diagnostic ability of skin cancer clinics. This will be the first project to quantify the role of skin clinics in the diagnosis of skin cancer in the community, and in particular their case volume, casemix and diagnostic accuracy, and assess these measures in relation to a comparable sample of general practitioners. Queensland is an ideal location for a study of this type due to its high incidence of both types of skin cancer.Read moreRead less
The Burden Of Cancer - Prevention, Treatments, Costs, And Related Diseases
Funder
National Health and Medical Research Council
Funding Amount
$311,860.00
Summary
This research aims to increase knowledge on the development, optimal treatment, and costs of cancer and the associated risk factors, by applying advanced disease burden measures to comprehensive data gathered from several established and novel databases. This knowledge is important in advancing our understanding of those most vulnerable to cancer and in developing appropriate preventive strategies and health care for those at highest risk.
Osteoporotic Fracture-Mortality Association And The Effect Of Anti-osteoporosis Treatment: A Multinational Study
Funder
National Health and Medical Research Council
Funding Amount
$84,800.00
Summary
Osteoporosis burden is due primarily to osteoporotic fractures resulting in economic and public health burden, increased disability, further fracture risk and more importantly early death. However, it remains under-treated although treatment reduces the number of fractures and may reduce early death. This study aims to understand which types of fractures result in early death and for which age groups and whether osteoporosis treatment does or does not reduce early death.
Integration Of Epidemiological, Biological, And Health Services Data In Cancer Research
Funder
National Health and Medical Research Council
Funding Amount
$290,032.00
Summary
Improved understanding of carcinogenic mechanisms, such as the importance of gene and environment interaction, has placed increased emphasis on the need for studies combining biological and epidemiological data. The proposed research program incorporates a number of cross-disciplinary studies which bridge classical epidemiology and basic science and strive to improve the clinical relevance and translational potential of research outcomes.
Improving Cancer Outcomes In Under-studied Cancers By Understanding Their Risk Factors And Patterns Of Cancer Care.
Funder
National Health and Medical Research Council
Funding Amount
$421,747.00
Summary
Cancer is the second leading cause of disease burden in Australia. Much can be done to reduce this burden through effective cancer prevention and ensuring all patients receive optimal evidence-based care. This research focuses on thyroid, kidney and ovarian cancer and aims to increase knowledge of these cancers’ causes and to investigate variation in patient care and its impact on outcomes. Ultimately the objective of the work is to decrease Australia’s cancer burden.